1-Piperidine propionic acid is effective in reducing HCC development and fatty acid accumulation in experimental liver carcinogenesis
P. Guerra,G. Villano,M.G. Ruvoletto,A. Biasiolo,S. Quarta,S. Cagnin,A. Martini,C.R. Gordillo,C. Gil-Pitarch,I. Gonzalez Recio,S. Cannito,E. Trevellin,M. Guido,R. Vettor,M. Parola,P. Angeli,M.L. Martínez-Chantar,P. Pontisso
DOI: https://doi.org/10.1016/j.dld.2024.01.024
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Introduction hepatocellular carcinoma (HCC) and metabolic dysfunction-associated steatotic liver disease (MASLD) are two major problems in modern hepatology since their incidence is increasing and specific treatments are lacking. Protease-activated receptor 2 (PAR2) is a member of G protein-coupled receptors and has been associated with lipid metabolism dysregulation and cancer progression, becoming an interesting therapeutic target. Recent results indicate that PAR2 is activated by SerpinB3, a serin-protease inhibitor involved in fibrosis and oncogenesis and is inhibited by the small molecule 1-Piperidine propionic Acid (1-PPA). Aim this study aims to investigate the effect of 1-PPA in steatosis progression and HCC development. Method in a mouse model of liver carcinogenesis, wild-type (BC/WT), knocked-out (BC/KO) and transgenic (C57/TG) mice for SerpinB3 were injected with diethylnitrosamine (DEN) and fed with CDAA diet in the presence or absence of 1-PPA for 26 weeks. Human preadipocytes were cultured in vitro with different concentrations of SerpinB3 (SB3) and 1-PPA. Primary hepatocytes extracted from C57 wild-type mice were treated with different steatogenic conditions (oleic acid, methionine-choline deficient (MCD) and SB3), different concentrations of 1-PPA and/or an inhibitor of VLDL formation/export: lomitapide. Results the presence of SerpinB3 in mice was associated with larger liver tumours, showing high steatosis content and this effect was reverted by 1-PPA. Mice treated with 1-PPA showed liver reduction of ER stress-related genes and in primary hepatocytes, this compound determined a reduction of ROS accumulation. Proteomic analysis revealed that 1-PPA determined a reduction in lipid metabolism and cancer-development-associated pathways. Human preadipocytes treated with SerpinB3 showed increased production of pro-adipogenic C/EBP-beta which was inhibited by administration of 1-PPA. Primary hepatocytes treated with steatogenic conditions and 1-PPA showed a reduction in lipid body accumulation, compared to controls. Simultaneous treatment with lomitapide erased the effect of 1-PPA, suggesting the involvement of VLDL formation/export in the mechanism of 1-PPA-associated lipid reduction. In agreement, 1-PPA treatment in mice was associated with higher levels of triglycerides in serum. Conclusion PAR2 inhibition by 1-PPA leads to reduced liver cancer development, associated with lower lipid accumulation, favoured, at least in part by an increased VLDL secretion.
gastroenterology & hepatology